130 related articles for article (PubMed ID: 10683516)
1. The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells.
Wang HY; Jiang XM; Ganea D
J Neuroimmunol; 2000 Apr; 104(1):68-78. PubMed ID: 10683516
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
Delgado M; Ganea D
J Neuroimmunol; 2000 Oct; 110(1-2):97-105. PubMed ID: 11024538
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
Delgado M; Ganea D
J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
[TBL] [Abstract][Full Text] [Related]
5. Pituitary adenylate-cyclase-activating polypeptide stimulates proto-oncogene expression and activates the AP-1 (c-Fos/c-Jun) transcription factor in AR4-2J pancreatic carcinoma cells.
Schäfer H; Zheng J; Gundlach F; Günther R; Siegel EG; Fölsch UR; Schmidt WE
Eur J Biochem; 1996 Dec; 242(3):467-76. PubMed ID: 9022670
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
Delgado M; Munoz-Elias EJ; Kan Y; Gozes I; Fridkin M; Brenneman DE; Gomariz RP; Ganea D
J Biol Chem; 1998 Nov; 273(47):31427-36. PubMed ID: 9813054
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
Delgado M; Ganea D
J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.
Martinez C; Delgado M; Gomariz RP; Ganea D
J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
10. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
Delgado M; Sun W; Leceta J; Ganea D
J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
Delgado M; Ganea D
J Biol Chem; 2001 Jan; 276(1):369-80. PubMed ID: 11029467
[TBL] [Abstract][Full Text] [Related]
14. Successive occupancy by immediate early transcriptional factors of the tyrosine hydroxylase gene TRE and CRE sites in PACAP-stimulated PC12 pheochromocytoma cells.
Yukimasa N; Isobe K; Nagai H; Takuwa Y; Nakai T
Neuropeptides; 1999 Dec; 33(6):475-82. PubMed ID: 10657527
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
Delgado M; Leceta J; Gomariz RP; Ganea D
J Immunol; 1999 Oct; 163(7):3629-35. PubMed ID: 10490956
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of cytokine expression in murine lymphocytes by PACAP and VIP.
Tang H; Sun L; Xin Z; Ganea D
Ann N Y Acad Sci; 1996 Dec; 805():768-78. PubMed ID: 8993475
[TBL] [Abstract][Full Text] [Related]
19. The neuropeptides VIP/PACAP and T cells: inhibitors or activators?
Ganea D; Delgado M
Curr Pharm Des; 2003; 9(12):997-1004. PubMed ID: 12678866
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
Delgado M; Ganea D
J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
